Indian stocks: Visit www.stage2stocks.com →

Black Diamond Therapeutics, Inc.

Stage 1 · Basing · week 8

As of Oct 22, 2026, Black Diamond Therapeutics is in Stage 1, the basing phase, now in week 8 (since Sep 1, 2026). It closed at $2.08, 57.3% below its 52-week high and below its 200-day average, which is falling.

Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. More about the company

$2.08
+0.00% today
$119M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Basing, not in an uptrend yet

Setup score

—

Momentum

Steady

Edge

—

Is BDTX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S2 21w
S4 32w
S2 21w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 5w → S3 8w → S4 7w → S1 4w → S2 21w → S3 6w → S2 7w → S3 2w → S4 32w → S1 7w → S2 21w → S3 7w → S4 11w → S1 8w → S4 11w → S1 7w current
Total tracked: 165 weeks across 16 stage runs.

BDTX among Biotechnology341st of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…341BDTXStage 1 · wk 825+9.5%
vs 52W High
-57.3%
$1.61 lo$4.87 hi
57.3% below 52W high
Stock is basing below old highs. A volume-backed breakout to new highs would be the Stage 2 signal to watch.
Stage Maturity
Week 8
1w13w26w
Week 8, base building
How long this stock has been basing. Longer bases can produce stronger breakouts, but the breakout itself is the signal.
vs 200 DMA
-6.3%
200 DMA: $2.22 · sloping down
Stock is testing its 200 DMA as part of the base. Reclaiming and holding above it is a key Stage 2 prerequisite.
Rel Volume
1.19x
vs 50-day avg
Volume in Stage 1 basing is typically quiet. A surge in volume on an upside breakout is the signal to watch.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
+9.5%
3M
+18.2%
6M
-32.9%
YTD
-16.5%
1Y
-47.5%
Scan Membership
Breakout Watch
Latest: 2024-08-14
5 appearances in last 60 days. First seen: 2020-12-04.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S1
Wk 8 · Vol 1.19x
2026-10-21S1
Wk 8 · Vol 3.59x
2026-10-20S1
Wk 7 · Vol 3.47x
2026-10-19S1
Wk 7 · Vol 1.37x
2026-10-16S1
Wk 7 · Vol 0.89x
2026-10-15S1
Wk 7 · Vol 1.03x
2026-10-14S1
Wk 7 · Vol 1.78x
2026-10-13S1
Wk 6 · Vol 1.95x
2026-10-12S1
Wk 6 · Vol 0.64x
2026-10-09S1
Wk 6 · Vol 0.76x
2026-10-08S1
Wk 6 · Vol 1.32x
2026-10-07S1
Wk 6 · Vol 0.93x
Moving averages & range
50 DMA
$1.98
200 DMA
$2.22
52W High
$4.87
52W Low
$1.61
5D Low
$1.72
Resistance levels (recent highs)
20d High
$2.08
60d High
$2.27
120d High
$3.60
250d High
$4.87
Next resistance
+9.1%
to 60d High
ROE
-37.2%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 1.2

Black Diamond Therapeutics: quick answers

What stage is Black Diamond Therapeutics in?

As of Oct 22, 2026, Black Diamond Therapeutics (BDTX) is in Stage 1, the basing phase. It entered Stage 1 on Sep 1, 2026 and is in week 8. What the four stages mean

Is Black Diamond Therapeutics in an uptrend?

Not yet. Black Diamond Therapeutics is in Stage 1, a base that can come before an uptrend. It trades 6.3% below its 200-day average, which is falling.

How far is Black Diamond Therapeutics from its 52-week high?

Black Diamond Therapeutics closed at $2.08 on Oct 22, 2026, 57.3% below its 52-week high of $4.87. Its 52-week low is $1.61.

How has Black Diamond Therapeutics performed over the past year?

As of Oct 22, 2026, Black Diamond Therapeutics is down 47.5% over the past year and down 16.5% so far in 2026.

Which sector and industry is Black Diamond Therapeutics in?

Black Diamond Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.